ACLX - Arcellx, Inc.
About Arcellx, Inc. (https://arcellx.com)
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Rami Elghandour | Chairman of the Board, Chief Executive Officer & President | 1979 | $1,383,771 USD |
| Michelle Lim Gilson | Chief Financial Officer | 1993 | $878,017 USD |
| Christopher R. Heery | Chief Medical Officer | 1981 | $794,520 USD |
| Neeraj Teotia | Chief Commercial Officer | 1975 | $461,949 USD |
| Aileen Fernandes | Chief Operating Officer | – | – |
| Heba Nowyhed | Chief Scientific Officer | – | – |
| Helen Kim | VP & Head of Regulatory Affairs | – | – |
| Kate Aiken | Chief People Officer | – | – |
| Maryam Abdul-Kareem | General Counsel & Chief Legal Officer | – | – |
| Myesha Lacy | Chief Investor & Communications Officer | – | – |
| Narinderjeet Singh | Chief Technical Officer | 1972 | – |